Latest

3 stories

Hide weekly roundups

Wednesday, September 23

AC Immune reports positive week-100 safety and immunogenicity data for ACI-7104 in Parkinson's trial

All primary endpoints of Part 1 of the VacSYn Phase 2 trial were met, with the company planning FDA discussions on next steps in early 2027.

SEC filing

Thursday, August 20

Clinical readoutAC Immune SA

AC Immune reports positive early Phase 1 data for NLRP3 inhibitor ACI-19764

Interim results show the oral drug candidate was well tolerated and reached the brain, with a cardiovascular risk cohort now dosing and full data due in H1 2027.

SEC filing

Tuesday, August 11

Regulatory milestoneAC Immune SA

AC Immune wins FDA Fast Track and IND clearance for Parkinson's candidate ACI-7104

The IND clearance lets the ongoing Phase 2 VacSYn trial add U.S. sites, with full Part 1 week-100 results still due in the second half of 2026.

SEC filing